Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 5.46 | -0.91% | -0.05 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | -0.91% | |
Shooting Star Candlestick | Bearish | -0.91% | |
Doji - Bearish? | Reversal | -0.91% | |
Earnings Movers | Other | -0.91% | |
Up 3 Days in a Row | Strength | -0.91% | |
Upper Bollinger Band Touch | Strength | -0.91% | |
50 DMA Resistance | Bearish | 0.55% | |
Crossed Above 20 DMA | Bullish | 0.55% | |
Earnings Movers | Other | 0.55% | |
Upper Bollinger Band Touch | Strength | 0.55% |
Alert | Time |
---|---|
Shooting Star Candlestick Entry | 34 minutes ago |
Fell Below Previous Day's Low | 34 minutes ago |
Down 2 % | 34 minutes ago |
60 Minute Opening Range Breakdown | about 1 hour ago |
Down 1% | about 2 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/14/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.17 |
52 Week Low | 2.0902 |
Average Volume | 191,129 |
200-Day Moving Average | 4.88 |
50-Day Moving Average | 5.54 |
20-Day Moving Average | 5.12 |
10-Day Moving Average | 5.15 |
Average True Range | 0.36 |
RSI (14) | 55.36 |
ADX | 14.33 |
+DI | 33.41 |
-DI | 16.66 |
Chandelier Exit (Long, 3 ATRs) | 4.78 |
Chandelier Exit (Short, 3 ATRs) | 5.48 |
Upper Bollinger Bands | 5.58 |
Lower Bollinger Band | 4.65 |
Percent B (%b) | 0.92 |
BandWidth | 18.17 |
MACD Line | -0.07 |
MACD Signal Line | -0.13 |
MACD Histogram | 0.0668 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.26 | ||||
Resistance 3 (R3) | 6.29 | 6.08 | 6.14 | ||
Resistance 2 (R2) | 6.08 | 5.89 | 6.06 | 6.09 | |
Resistance 1 (R1) | 5.79 | 5.77 | 5.94 | 5.76 | 6.05 |
Pivot Point | 5.58 | 5.58 | 5.65 | 5.56 | 5.58 |
Support 1 (S1) | 5.29 | 5.39 | 5.44 | 5.26 | 4.97 |
Support 2 (S2) | 5.08 | 5.27 | 5.06 | 4.93 | |
Support 3 (S3) | 4.79 | 5.08 | 4.89 | ||
Support 4 (S4) | 4.76 |